Retrometabolic drug design

Last updated

In the field of drug discovery, retrometabolic drug design is a strategy for the design of safer drugs either using predictable metabolism to an inactive moiety or using targeted drug delivery approaches. The phrase retrometabolic drug design was coined by Nicholas Bodor. [1] The method is analogous to retrosynthetic analysis where the synthesis of a target molecule is planned backwards. In retrometabolic drug design, metabolic reaction information of drugs is used to design parent drugs whose metabolism and distribution can be controlled to target and eliminate the drug to increase efficacy and minimize undesirable side effects. The new drugs thus designed achieve selective organ and/or therapeutic site drug targeting and produce safe therapeutic agents and safe environmental chemicals. These approaches represent systematic methodologies that thoroughly integrate structure-activity (SAR) and structure-metabolism (SMR) relationships and are aimed at designing safe, locally active compounds with improved therapeutic index (ratio of benefit vs. side effect). [2] [3] [4] [5] [6]

Contents

Retrometabolic drug design loop that includes chemical delivery systems (CDS) design and soft drug (SD) design. Possible metabolic pathways for drugs (D) in general are indicated within the dashed box. Retrometabolic Drug Design loop.gif
Retrometabolic drug design loop that includes chemical delivery systems (CDS) design and soft drug (SD) design. Possible metabolic pathways for drugs (D) in general are indicated within the dashed box.

Classification

The concept of retrometabolic drug design encompasses two distinct approaches. One approach is the design of soft drugs (SDs), [4] [7] [8] [9] [10] [11] [12] [13] [14] [15] new, active therapeutic agents, often isosteric or isolelectronic analogs of a lead compound, with a chemical structure specifically designed to allow predictable metabolism into inactive metabolites after exerting their desired therapeutic effect(s). The other approach is the design of chemical delivery systems (CDSs). [4] [16] [17] [18] [19] [20] [21] [22] [23] CDSs are biologically inert molecules intended to enhance drug delivery to a particular organ or site and requiring several conversion steps before releasing the active drug.

Although both retrometabolic design approaches involve chemical modifications of the molecular structure and both require enzymatic reactions to fulfill drug targeting, the principles of SD and CDS design are distinctly different. While CDSs are inactive as administered and sequential enzymatic reactions provide the differential distribution and ultimately release the active drug, SDs are active as administered and are designed to be easily metabolized into inactive species. Assuming an ideal situation, with a CDS the drug is present at the site and nowhere else in the body because enzymatic processes destroy the drug at those sites. Whereas, CDSs are designed to achieve drug targeting at a selected organ or site, SDs are designed to afford a differential distribution that can be regarded as reverse targeting.

Soft drugs

Since its introduction by Nicholas Bodor in the late 1970s, the soft drug concept generated considerable research both in academic and in industrial settings. Bodor defined soft drugs as biologically active, therapeutically useful chemical compounds characterized by a predictable and controllable in vivo metabolism to non-toxic moieties after they achieve their therapeutic role. [24] There are several rationally designed soft drugs that have either already reached the market, such as

or are in late-stage development (budiodarone, celivarone, AZD3043, tecafarin). [25] There are also compounds that can be considered as soft chemicals (e.g., malathion) or soft drugs (e.g., articaine, methylphenidate) even though they were not developed as such. [25]

Chemical delivery systems

Since their introduction in the early 1980s, CDSs have also generated considerable research work, especially for brain and eye targeting of various therapeutic agents, including those that cannot cross the blood–brain barrier or the blood–retinal barrier on their own. Within this approach, three major general CDS classes have been identified:

  • Enzymatic physicochemical-based (e.g., brain-targeting) CDSs: exploit site-specific traffic properties by sequential metabolic conversions that result in considerably altered properties
  • Site-specific enzyme-activated (e.g., eye-targeting) CDSs: exploit specific enzymes found primarily, exclusively, or at higher activity at the site of action
  • Receptor-based transient anchor-type (e.g., lung-targeting) CDSs: provide enhanced selectivity and activity through transient, reversible binding at the receptor

This concept has been extended to many drugs and peptides, its importance illustrated by the fact that its first applications and uses were published in Science [26] [27] [28] in 1975, 1981 and 1983. Its extension to the targeted brain-delivery of neuropeptides was included by the Harvard Health Letter [29] as one of the top 10 medical advances of 1992. Several compounds have reached advanced clinical development phase, such as

  • E2-CDS (Estredox) for the brain-targeted delivery of estradiol [30] and
  • betaxoxime for the eye-targeted delivery of betaxolol [31]

In the first example above, brain-targeted CDSs employ a sequential metabolic conversion of a redox-based targetor moiety, which is closely related to the ubiquitous NAD(P)H ⇌ NAD(P)+ coenzyme system, to exploit the unique properties of the blood–brain barrier (BBB). After enzymatic oxidation of the NADH type drug conjugate to its corresponding NAD+- drug, the still inactive precursor, "locks-in" behind the BBB to provide targeted and sustained CNS-delivery of the compound of interest.

The second example involves eye-specific delivery of betaxoxime, the oxime derivative of betaxolol. The administered, inactive β-amino-ketoxime is converted to the corresponding ketone via oxime hydrolase, an enzyme recently identified with preferential activity in the eye, and then stereospecifically reduced to its alcohol form. IOP-lowering activity is demonstrated without producing the active β-blockers systemically, making them void of any cardiovascular activity, a major drawback of classical antiglaucoma agents. Because of the advantages provided by this unique eye-targeting profile, oxime-based eye-targeting CDSs could replace the β-blockers currently used for ophthalmic applications.

History and significance

These retrometabolic design strategies were introduced by Nicholas Bodor, one of the first and most prominent advocates for the early integration of metabolism, pharmacokinetic and general physicochemical considerations in the drug design process. [32] [33] [34] These drug design concepts recognize the importance of design-controlled metabolism and directly focus not on the increase of activity alone but on the increase of the activity/toxicity ratio (therapeutic index) in order to deliver the maximum benefit while also reducing or eliminating unwanted side effects. The importance of this field is reviewed in a book dedicated to the subject (Bodor, N.; Buchwald, P.; Retrometabolic Drug Design and Targeting, 1st ed., Wiley & Sons, 2012), as well as by a full chapter of Burger's Medicinal Chemistry and Drug Design, 7th ed. (2010) with close to 150 chemical structures and more than 450 references. [35] At the time of its introduction, the idea of designed-in metabolism represented a significant novelty and was against mainstream thinking then in place that instead focused on minimizing or entirely eliminating drug metabolism. Bodor's work on these design concepts developed during the late 1970s and early 1980s, and came to prominence during the mid-1990s. Loteprednol etabonate, a soft corticosteroid designed and patented [36] [37] by Bodor received final Food and Drug Administration (FDA) approval in 1998 as the active ingredient of two ophthalmic preparations (Lotemax and Alrex), currently the only corticosteroid approved by the FDA for use in all inflammatory and allergy-related ophthalmic disorders. Its safety for long-term use [38] further supports the soft drug concept, and in 2004, loteprednol etabonate [39] [40] [41] was also approved as part of a combination product (Zylet). A second generation of soft corticosteroids such as etiprednol dicloacetate [42] is in development for a full spectrum of other possible applications such as nasal spray for rhinitis or inhalation products for asthma.

The soft drug concept ignited research work in both academic (e.g., Aston University, Göteborg University, Okayama University, Uppsala University, University of Iceland, University of Florida, Université Louis Pasteur, Yale University) and industrial (e.g., AstraZeneca, DuPont, GlaxoSmithKline, IVAX, Janssen Pharmaceutica, Nippon Organon, Novartis, ONO Pharmaceutical, Schering AG) settings. Besides corticosteroids, various other therapeutic areas have been pursued such as soft beta-blockers, soft opioid analgetics, soft estrogens, soft beta-agonists, soft anticholinergics, soft antimicrobials, soft antiarrhythmic agents, soft angiotensin converting enzyme (ACE) inhibitors, soft dihydrofolate reductase (DHFR) inhibitors, soft cancineurin inhibitors (soft immunosuppressants), soft matrix metalloproteinase (MMP) inhibitors, soft cytokine inhibitors, soft cannabinoids, soft Ca2+ channel blockers (see [35] for a recent review).

Following the introduction of the CDS concepts, work along those lines started in numerous pharmaceutical centers around the world, and brain-targeting CDSs were explored for many therapeutic agents such as steroids (testosterone, progestins, estradiol, dexamethasone), anti-infective agents (penicillins, sulfonamides), antivirals (acyclovir, trifluorothymidine, ribavirin), antiretrovirals (AZT, ganciclovir), anticancer agents (Lomustine, chlorambucil), neurotransmitters (dopamine, GABA), nerve growth factor (NGF) inducers, anticonvulsants (Phenytoin, valproate, stiripentol), Ca2+ antagonists (felodipine), MAO inhibitors, NSAIDs and neuropeptides (tryptophan, Leu-enkephalin analogs, TRH analogs, kyotorphin analogs). A number of new chemical entities (NCE) were developed based on these principles, such as E2-CDS (Estredox [30] or betaxoxime [31] are in advanced clinical development phases.

A review of ongoing research using the general retrometabolic design approaches is conducted biennially at the Retrometabolism Based Drug Design and Targeting Conference, an international series of symposia developed and organized by Nicholas Bodor. Proceedings of each conference held have been published in the international pharmaceutical journal Pharmazie. Past conferences, and their published proceedings are:

  • May 1997, Amelia Island, Florida; Pharmazie52(7) S1, 1997
  • May 1999, Amelia Island, Florida; Pharmazie55(3), 2000
  • May 2001, Amelia Island Florida; Pharmazie57(2), 2002
  • May 2003, Palm Coast, Florida; Pharmazie59(5), 2004
  • May 2005, Hakone, Japan; Pharmazie61(2), 2006
  • June 2007, Göd, Hungary; Pharmazie63(3), 2008
  • May 2009, Orlando, Florida; Pharmazie65(6), 2010
  • June 2011, Graz, Austria; Pharmazie67(5), 2012
  • May 2013, Orlando, Florida; Pharmazie69(6), 2014
  • October 2015, Orlando, Florida.

Related Research Articles

<span class="mw-page-title-main">Pharmacology</span> Branch of biology concerning drugs

Pharmacology is a branch of medicine, biology and pharmaceutical sciences concerned with drug or medication action, where a drug may be defined as any artificial, natural, or endogenous molecule which exerts a biochemical or physiological effect on the cell, tissue, organ, or organism. More specifically, it is the study of the interactions that occur between a living organism and chemicals that affect normal or abnormal biochemical function. If substances have medicinal properties, they are considered pharmaceuticals.

<span class="mw-page-title-main">Blood–brain barrier</span> Semipermeable capillary border that allows selective passage of blood constituents into the brain

The blood–brain barrier (BBB) is a highly selective semipermeable border of endothelial cells that prevents solutes in the circulating blood from non-selectively crossing into the extracellular fluid of the central nervous system where neurons reside. The blood–brain barrier is formed by endothelial cells of the capillary wall, astrocyte end-feet ensheathing the capillary, and pericytes embedded in the capillary basement membrane. This system allows the passage of some small molecules by passive diffusion, as well as the selective and active transport of various nutrients, ions, organic anions, and macromolecules such as glucose and amino acids that are crucial to neural function.

<span class="mw-page-title-main">Route of administration</span> Path by which a drug, fluid, poison, or other substance is taken into the body

A route of administration in pharmacology and toxicology is the way by which a drug, fluid, poison, or other substance is taken into the body.

<span class="mw-page-title-main">Esmolol</span> Class II antiarrhythmic drug

Esmolol, sold under the brand name Brevibloc, is a cardio selective beta1 receptor blocker with rapid onset, a very short duration of action, and no significant intrinsic sympathomimetic or membrane stabilising activity at therapeutic dosages.

<span class="mw-page-title-main">Dendrimer</span>

Dendrimers are highly ordered, branched polymeric molecules. Synonymous terms for dendrimer include arborols and cascade molecules. Typically, dendrimers are symmetric about the core, and often adopt a spherical three-dimensional morphology. The word dendron is also encountered frequently. A dendron usually contains a single chemically addressable group called the focal point or core. The difference between dendrons and dendrimers is illustrated in the top figure, but the terms are typically encountered interchangeably.

Transcytosis is a type of transcellular transport in which various macromolecules are transported across the interior of a cell. Macromolecules are captured in vesicles on one side of the cell, drawn across the cell, and ejected on the other side. Examples of macromolecules transported include IgA, transferrin, and insulin. While transcytosis is most commonly observed in epithelial cells, the process is also present elsewhere. Blood capillaries are a well-known site for transcytosis, though it occurs in other cells, including neurons, osteoclasts and M cells of the intestine.

<span class="mw-page-title-main">Drug delivery</span> Methods for delivering drugs to target sites

Drug delivery refers to approaches, formulations, manufacturing techniques, storage systems, and technologies involved in transporting a pharmaceutical compound to its target site to achieve a desired therapeutic effect. Principles related to drug preparation, route of administration, site-specific targeting, metabolism, and toxicity are used to optimize efficacy and safety, and to improve patient convenience and compliance. Drug delivery is aimed at altering a drug's pharmacokinetics and specificity by formulating it with different excipients, drug carriers, and medical devices. There is additional emphasis on increasing the bioavailability and duration of action of a drug to improve therapeutic outcomes. Some research has also been focused on improving safety for the person administering the medication. For example, several types of microneedle patches have been developed for administering vaccines and other medications to reduce the risk of needlestick injury.

<span class="mw-page-title-main">Loteprednol</span>

Loteprednol is a topical corticosteroid used to treat inflammations of the eye. It is marketed by Bausch and Lomb as Lotemax and Loterex.

Pharmacokinetics, sometimes abbreviated as PK, is a branch of pharmacology dedicated to determining the fate of substances administered to a living organism. The substances of interest include any chemical xenobiotic such as: pharmaceutical drugs, pesticides, food additives, cosmetics, etc. It attempts to analyze chemical metabolism and to discover the fate of a chemical from the moment that it is administered up to the point at which it is completely eliminated from the body. Pharmacokinetics is the study of how an organism affects a drug, whereas pharmacodynamics (PD) is the study of how the drug affects the organism. Both together influence dosing, benefit, and adverse effects, as seen in PK/PD models.

Therapeutic ultrasound refers generally to any type of ultrasonic procedure that uses ultrasound for therapeutic benefit. Physiotherapeutic ultrasound was introduced into clinical practice in the 1950s, with lithotripsy introduced in the 1980s. Others are at various stages in transitioning from research to clinical use: HIFU, targeted ultrasound drug delivery, trans-dermal ultrasound drug delivery, ultrasound hemostasis, cancer therapy, and ultrasound assisted thrombolysis It may use focused ultrasound (FUS) or unfocused ultrasound.

<span class="mw-page-title-main">Transferrin receptor 1</span>

Transferrin receptor protein 1 (TfR1), also known as Cluster of Differentiation 71 (CD71), is a protein that in humans is encoded by the TFRC gene. TfR1 is required for iron import from transferrin into cells by endocytosis.

Microbubbles (MBs) are bubbles smaller than one hundredth of a millimetre in diameter, but larger than one micrometre. They have widespread application in industry, life science, and medicine. The composition of the bubble shell and filling material determine important design features such as buoyancy, crush strength, thermal conductivity, and acoustic properties.

A codrug or "mutual prodrug" consists of two synergistic drugs chemically linked together to a single molecule, in order to improve the drug delivery properties of one or both drugs.

Drug delivery to the brain is the process of passing therapeutically active molecules across the blood–brain barrier into the brain. This is a complex process that must take into account the complex anatomy of the brain as well as the restrictions imposed by the special junctions of the blood–brain barrier.

<span class="mw-page-title-main">Diffuse intrinsic pontine glioma</span>

Diffuse midline glioma (DMG), previously called Diffuse Intrinsic Pontine Glioma (DIPG) is a fatal tumour that arises in the brainstem; most commonly in the pons or thalamus. DMG is believed to be caused by genetic mutations that cause epigenetic changes in cells of the developing nervous system, resulting in a failure of the cells to properly differentiate. Currently, the standard of care is fractionated external beam radiotherapy, as the tumour location precludes surgery, and chemotherapy has shown to be ineffective, however the estimated survival post-diagnosis remains only 9-15 months.

Nanoparticles for drug delivery to the brain is a method for transporting drug molecules across the blood–brain barrier (BBB) using nanoparticles. These drugs cross the BBB and deliver pharmaceuticals to the brain for therapeutic treatment of neurological disorders. These disorders include Parkinson's disease, Alzheimer's disease, schizophrenia, depression, and brain tumors. Part of the difficulty in finding cures for these central nervous system (CNS) disorders is that there is yet no truly efficient delivery method for drugs to cross the BBB. Antibiotics, antineoplastic agents, and a variety of CNS-active drugs, especially neuropeptides, are a few examples of molecules that cannot pass the BBB alone. With the aid of nanoparticle delivery systems, however, studies have shown that some drugs can now cross the BBB, and even exhibit lower toxicity and decrease adverse effects throughout the body. Toxicity is an important concept for pharmacology because high toxicity levels in the body could be detrimental to the patient by affecting other organs and disrupting their function. Further, the BBB is not the only physiological barrier for drug delivery to the brain. Other biological factors influence how drugs are transported throughout the body and how they target specific locations for action. Some of these pathophysiological factors include blood flow alterations, edema and increased intracranial pressure, metabolic perturbations, and altered gene expression and protein synthesis. Though there exist many obstacles that make developing a robust delivery system difficult, nanoparticles provide a promising mechanism for drug transport to the CNS.

<span class="mw-page-title-main">Itrocinonide</span> Chemical compound

Itrocinonide is a synthetic glucocorticoid corticosteroid which was never marketed.

<span class="mw-page-title-main">Sofpironium bromide</span>

Sofpironium bromide is a drug used to treat hyperhidrosis. It was approved in Japan in 2020 as a 5% gel for the treament of primary axillary hyperhidrosis (PAH).

<span class="mw-page-title-main">Focused ultrasound for intracranial drug delivery</span> Medical technique

Focused ultrasound for intracrainial drug delivery is a non-invasive technique that uses high-frequency sound waves to disrupt tight junctions in the blood–brain barrier (BBB), allowing for increased passage of therapeutics into the brain. The BBB normally blocks nearly 98% of drugs from accessing the central nervous system, so FUS has the potential to address a major challenge in intracranial drug delivery by providing targeted and reversible BBB disruption. Using FUS to enhance drug delivery to the brain could significantly improve patient outcomes for a variety of diseases including Alzheimer's disease, Parkinson's disease, and brain cancer.

Convection-enhanced delivery (CED) is method of drug delivery in which drug is delivered into using bulk flow rather than conventional diffusion into the brain. This is done by utilizing catheters inserted into the target region of the brain and utilizing pressure to deliver the therapeutic to a target region. CED has been used to delivery drugs to the central nervous system (CNS) for diseases such as cancer, epilepsy, and Parkinson’s disease. CED has been used to deliver drugs to the CNS for its ability to bypass the blood–brain barrier (BBB) and target specific regions for targeted treatment, but current techniques using CED have failed to progress past clinical trials due to a variety of physical limitations associated with CED itself.

References

  1. ↑ Bodor N, Buchwald P (2012). Retrometabolic drug design and targeting. Hoboken, N.J.: John Wiley & Sons. p. 418. ISBN   978-0-470-94945-0.
  2. ↑ Bodor, N.; Buchwald, P. (1999). "Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems". Adv. Drug Deliv. Rev. 36 (2–3): 229–254. doi:10.1016/s0169-409x(98)00090-8. PMID   10837718.
  3. ↑ Miller, G. (2002). "Breaking down barriers". Science. 297 (5584): 1116–1118. doi:10.1126/science.297.5584.1116. PMID   12183610. S2CID   70373003.
  4. 1 2 3 Regier, D.A.; Boyd, J.H.; Burke, J.D. Jr; Rae, D.S.; Myers, J.K.; Kramer, M.; Robins, L.N.; George, L.K.; Karno, M.; Locke, B.Z. (1988). "One-month prevalence of mental disorders in the United States". Arch. Gen. Psychiatry. 45 (11): 977–986. doi:10.1001/archpsyc.1988.01800350011002. PMID   3263101.
  5. ↑ Crone; Thompson, A.M. (1970). Crone, C.; Lassen, N.A. (eds.). Capillary Permeability: The Transfer of Molecules and Ions Between Capillary Blood and Tissue (C. ed.). Munksgaard: Copenhagen, Denmark. pp. 447–453.
  6. ↑ Oldendorf, W.H. (1974). "Lipid solubility and drug penetration of the blood–brain barrier". Proceedings of the Society for Experimental Biology and Medicine. 147 (3): 813–816. doi:10.3181/00379727-147-38444. PMID   4445171. S2CID   3156196.
  7. ↑ Rapoport, S.I. (1976). Blood-Brain Barrier in Psychology and Medicine. Raven Press, New York.
  8. ↑ Bradbury, M. (1979). The Concept of a Blood-Brain Barrier . Wiley, New York. ISBN   9780471996880.
  9. ↑ Bodor, N.; Brewster, M.E. (1983). "Problems of delivery of drugs to the brain". Pharmacol. Ther. 19 (3): 337–386. doi:10.1016/0163-7258(82)90073-0. PMID   6765182.
  10. ↑ Fenstermacher, J.D.; Rapoport, S.I. (1984). "The blood–brain barrier. In Microcirculation, Part 2". In Renkin, E.M.; Michel, C.C. (eds.). Handbook of Physiology, Section 2: The Cardiovascular System, Vol. 4. American Physiological Society, Bethesda, MD. pp. 969–1000.
  11. ↑ Goldstein, G.W.; Betz, A.L. (1986). "The blood–brain barrier". Sci. Am. 255 (3): 74–83. Bibcode:1986SciAm.255c..74G. doi:10.1038/scientificamerican0986-74. PMID   3749857.
  12. ↑ Bradbury, M.W.B., ed. (1992). Physiology and Pharmacology of the Blood-Brain Barrier, Handbook of Experimental Pharmacology, Vol. 103. Springer, Berlin.
  13. ↑ Begley, D.J. (1996). "The blood–brain barrier: principles for targeting peptides and drugs to the central nervous system". J. Pharm. Pharmacol. 48 (2): 136–146. doi:10.1111/j.2042-7158.1996.tb07112.x. PMID   8935161. S2CID   22909691.
  14. ↑ Schlossauer, B.; Steuer, H. (2002). "Comparative anatomy, physiology and in vitro models of the blood–brain and blood-retina barrier". Current Medicinal Chemistry - Central Nervous System Agents. 2 (3): 175–186. doi:10.2174/1568015023357978.
  15. ↑ Betz, A.L.; Goldstein, G.W. "Brain capillaries: structure and function". In Lajtha, A. (ed.). Structural Elements of the Nervous System; Handbook of Neurochemistry, Vol. 7. Plenum Press, New York. pp. 465–484.
  16. ↑ Pardridge, W.M. (1991). Peptide Drug Delivery to the Brain. Raven Press, New York.
  17. ↑ Abbott, N.J.; Bundgaard, M.; Cserr, H.F. (1986). "Comparative physiology of the blood–brain barrier". In Suckling, A.J.; Rumsby, M.G.; Bradbury, M.W.B. (eds.). The Blood-Brain Barrier in Health and Disease. Ellis Horwood: Chichester, UK. pp. 52–72.
  18. ↑ Lo, E.H.; Singhal, A.B.; Torchilin, V.P.; Abbott, N.J. (2001). "Drug delivery to damaged brain". Brain Res. Rev. 38 (1–2): 140–148. doi:10.1016/s0165-0173(01)00083-2. PMID   11750930. S2CID   23679546.
  19. ↑ Smith, Q.R. (1989). "Quantitation of blood–brain barrier permeability". In Neuwelt, E.A. (ed.). Implications of the Blood-Brain Barrier and its Manipulation. Plenum Press, New York. pp. 85–113.
  20. ↑ Stewart, P.A.; Tuor, U.I. (1994). "Blood-eye barriers in the rat: Correlation of ultrastructure with function". J. Comp. Neurol. 340 (4): 566–576. doi:10.1002/cne.903400409. PMID   8006217. S2CID   46222465.
  21. ↑ Siegal, T.; Zylber-Katz, E. (2002). "Strategies for increasing drug delivery to the brain: focus on brain lymphoma". Clin. Pharmacokinet. 41 (3): 171–186. doi:10.2165/00003088-200241030-00002. PMID   11929318. S2CID   24034568.
  22. ↑ Ehrlich, P. (1885). Das Sauerstoff Bedürfnis des Organismus: Eine farbenanalytische Studie (in German). Hirschwald, Berlin.
  23. ↑ Janzer, R.C.; Raff, M.C. (1987). "Astrocytes induce blood–brain barrier properties in endothelial-cells". Nature. 325 (6101): 253–257. Bibcode:1987Natur.325..253J. doi:10.1038/325253a0. PMID   3543687. S2CID   4311724.
  24. ↑ Bodor, Nicholas (1984). "Soft drugs: Principles and methods for the design of safe drugs". Medicinal Research Reviews. 4 (4): 449–469. doi:10.1002/med.2610040402. PMID   6387331. S2CID   11444679.
  25. 1 2 Bodor, N.; Buchwald, P. (2012). Retrometabolic Drug Design and Targeting. John Wiley & Sons, New York. ISBN   978-0-470-94945-0.
  26. ↑ Bodor, N.; Shek, E.; Higuchi, T. (1975). "Delivery of a quaternary pyridinium salt across the blood–brain barrier by its dihydropyridine derivative". Science. 190 (4210): 155–156. Bibcode:1975Sci...190..155B. doi:10.1126/science.1166305. PMID   1166305. S2CID   34242024.
  27. ↑ Bodor, N.; Farag, H.H.; Brewster, M.E. (1981). "Site-specific, sustained release of drugs to the brain". Science. 214 (4527): 1370–1372. Bibcode:1981Sci...214.1370B. doi:10.1126/science.7313698. PMID   7313698.
  28. ↑ Bodor, N.; Simpkins, J.W. (1983). "Redox delivery system for brain-specific, sustained release of dopamine". Science. 221 (4605): 65–67. Bibcode:1983Sci...221...65B. doi:10.1126/science.6857264. PMID   6857264.
  29. ↑ Thomas, P. (1993). "Top ten advances of 1992". Harvard Health Letter. 18: 1–4.
  30. 1 2 Bodor, N.; Buchwald, P. (2006). "Brain-targeted delivery of estradiol: therapeutic potential and results obtained with a chemical delivery system approach". Am. J. Drug Deliv. 4: 161–175. doi:10.2165/00137696-200604030-00004. S2CID   68203212.
  31. 1 2 Bodor, N.; Buchwald, P. (2005). "Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems". AAPS J. 7 (4): article 79 (E820-E833). doi:10.1208/aapsj070479. PMC   2750951 . PMID   16594634.
  32. ↑ Bodor, N. (1977). "Novel approaches for the design of membrane transport properties of drugs". In Roche, E.B. (ed.). Design of Biopharmaceutical Properties through Prodrugs and Analogs. Academy of Pharmaceutical Sciences; Washington, D.C. pp. 98–135.
  33. ↑ Bodor, N. (1982). "Designing safer drugs based on the soft drug approach". Trends Pharmacol. Sci. 3: 53–56. doi:10.1016/0165-6147(82)91008-2.
  34. ↑ Bodor, N. (1984). "Novel approaches to the design of safer drugs: Soft drugs and site-specific chemical delivery systems". Adv. Drug Res. 13: 255–331.
  35. 1 2 Retrometabolism-based drug design and targeting (2010). "3". In Abraham, D. (ed.). Burger's Medicinal Chemistry, Drug Discovery and Development; Vol. 2: Discovering Lead Molecules. Wiley & Sons; New York.
  36. ↑ Bodor, N. (1981). "Stéroïds doux exerçant une activité anti-inflammatoire. (Steroids having anti-inflammatory activity)". Belgian Patent BE889,563 (in French). Intl. Classif. C07J/A61K.
  37. ↑ Bodor, N. (1991). "Soft Steroids having anti-inflammatory activity". U.S. Patent 4,996,335.
  38. ↑ Ilyas, H.; Slonim, C.B.; Braswell, G.R.; Favetta, J.R.; Schulman, M. (2004). "Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis". Eye & Contact Lens. 30 (1): 10–13. doi:10.1097/01.icl.0000092071.82938.46. PMID   14722462. S2CID   42118787.
  39. ↑ Bodor, N.; Buchwald, P. (2002). "Design and development of a soft corticosteroid, loteprednol etabonate". In Schleimer, R.P.; O'Byrne, P.M.; Szefler, S.J.; Brattsand, R. (eds.). Inhaled Steroids in Asthma. Optimizing Effects in the Airways . Lung Biology in Health and Disease, Vol. 163. Marcel Dekker, New York. pp.  541–564. ISBN   9780824705855.
  40. ↑ Hermann, R.; Locher, M.; Siebert-Weigel, M.; LaVallee, N.; Derendorf, H. and Hochhaus, G. (2004). "Intranasal loteprednol etabonate in healthy male subjects: pharmacokinetics and effects on endogenous cortisol". J. Clin. Pharmacol. 44 (5): 510–519. doi:10.1177/0091270004264163. PMID   15102872. S2CID   28017806.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  41. ↑ Bodor, N.; Buchwald, P. (2006). "Corticosteroid design for the treatment of asthma: structural insights and the therapeutic potential of soft corticosteroids". Curr. Pharm. Des. 12 (25): 3241–3260. doi:10.2174/138161206778194132. PMID   17020532.
  42. ↑ Bodor, N. (1999). "Androstene Derivatives". U.S. Patent 5,981,517.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.